{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=C1+Esterase+Inhibitor&page=3",
    "query": {
      "intervention": "C1 Esterase Inhibitor",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 51,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=C1+Esterase+Inhibitor&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=C1+Esterase+Inhibitor&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T06:12:45.495Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07046806",
      "title": "Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Angioedema (HAE)",
        "Angioedema",
        "Bradykinin-mediated Angioedema",
        "C1 Inhibitor Deficiency"
      ],
      "interventions": [
        {
          "name": "Deucrictibant XR tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo comparator to XR tablet",
          "type": "DRUG"
        },
        {
          "name": "Deucrictibant 20 mg capsule",
          "type": "DRUG"
        },
        {
          "name": "Placebo comparator to 20 mg capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Institute for Asthma and Allergy",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2025-03-10",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-07-02",
      "last_synced_at": "2026-10-05T06:12:45.495Z",
      "location_count": 1,
      "location_summary": "Wheaton, Maryland",
      "locations": [
        {
          "city": "Wheaton",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07046806"
    },
    {
      "nct_id": "NCT02316353",
      "title": "A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema Types I and II"
      ],
      "interventions": [
        {
          "name": "C1-esterase inhibitor",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 126,
      "start_date": "2014-12-31",
      "completion_date": "2017-09-21",
      "has_results": true,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-10-05T06:12:45.495Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02316353"
    },
    {
      "nct_id": "NCT01035593",
      "title": "Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Rejection",
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "plasmapheresis and IVIG",
          "type": "PROCEDURE"
        },
        {
          "name": "recombinant C1 inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Pharming Technologies B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2010-12",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2012-02-17",
      "last_synced_at": "2026-10-05T06:12:45.495Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01035593"
    },
    {
      "nct_id": "NCT04307381",
      "title": "An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "Donidalorsen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2020-03-31",
      "completion_date": "2025-01-24",
      "has_results": true,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-10-05T06:12:45.495Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Santa Monica, California • Plymouth, Minnesota + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Plymouth",
          "state": "Minnesota"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04307381"
    },
    {
      "nct_id": "NCT02134314",
      "title": "C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "End Stage Renal Disease",
        "Kidney Failure",
        "Delayed Graft Function",
        "Ischemic Reperfusion Injury"
      ],
      "interventions": [
        {
          "name": "C1 Esterase Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 70,
      "start_date": "2014-09",
      "completion_date": "2017-03-13",
      "has_results": true,
      "last_update_posted_date": "2018-06-25",
      "last_synced_at": "2026-10-05T06:12:45.495Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02134314"
    },
    {
      "nct_id": "NCT01188564",
      "title": "Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "rhC1INH",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Saline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharming Technologies B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2011-01",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2015-08-07",
      "last_synced_at": "2026-10-05T06:12:45.495Z",
      "location_count": 15,
      "location_summary": "Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 12 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01188564"
    },
    {
      "nct_id": "NCT02547220",
      "title": "A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Antibody-Mediated Rejection (AMR)"
      ],
      "interventions": [
        {
          "name": "Cinryze®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 39,
      "start_date": "2016-05-20",
      "completion_date": "2019-05-31",
      "has_results": true,
      "last_update_posted_date": "2020-07-13",
      "last_synced_at": "2026-10-05T06:12:45.495Z",
      "location_count": 29,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02547220"
    },
    {
      "nct_id": "NCT03221842",
      "title": "Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Antibody-mediated Rejection"
      ],
      "interventions": [
        {
          "name": "C1-esterase inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2017-11-06",
      "completion_date": "2021-01-20",
      "has_results": true,
      "last_update_posted_date": "2022-07-29",
      "last_synced_at": "2026-10-05T06:12:45.495Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03221842"
    },
    {
      "nct_id": "NCT01359969",
      "title": "Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "rhC1INH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharming Technologies B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "13 Years",
        "sex": "ALL",
        "summary": "2 Years to 13 Years"
      },
      "enrollment_count": 57,
      "start_date": "2012-01-17",
      "completion_date": "2017-07-17",
      "has_results": true,
      "last_update_posted_date": "2024-03-29",
      "last_synced_at": "2026-10-05T06:12:45.495Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01359969"
    },
    {
      "nct_id": "NCT02247739",
      "title": "A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "Recombinant human C1 inhibitor",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Pharming Technologies B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2014-12",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2017-12-08",
      "last_synced_at": "2026-10-05T06:12:45.495Z",
      "location_count": 4,
      "location_summary": "Tampa, Florida • St Louis, Missouri • Lake Oswego, Oregon",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Lake Oswego",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02247739"
    }
  ]
}